BACHEM HOLDING AG Financials Bachem Holding AG OTC Markets
Equities
BCHMY
US05636G1058
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 9.585 USD | -3.15% |
|
+6.50% | +27.80% |
| Jul. 01 | RBC Initiates Bachem Coverage at Outperform | MT |
| May. 28 | Swiss Market Index Blinks Red Amid Fed, ECB Divergence Spotlight | MT |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 2,165 | 5,534 | 10,558 | 5,889 | 4,873 | 6,556 | - | - |
| Enterprise Value (EV) 1 | 2,251 | 5,618 | 10,490 | 5,858 | 4,575 | 6,477 | 6,629 | 6,861 |
| P/E ratio | 7.92 x | 14.2 x | 17.7 x | 58.3 x | 43.3 x | 57 x | 41.6 x | 34.6 x |
| Yield | 9.69% | 4.11% | 2.44% | 0.94% | 1.23% | 0.99% | 1.07% | 1.26% |
| Capitalization / Revenue | 6.9 x | 13.8 x | 21 x | 11.1 x | 8.44 x | 10.6 x | 8.14 x | 6.54 x |
| EV / Revenue | 7.17 x | 14 x | 20.8 x | 11 x | 7.92 x | 10.4 x | 8.23 x | 6.84 x |
| EV / EBITDA | 25.8 x | 45.8 x | 66.6 x | 36.5 x | 27.4 x | 35.9 x | 27.5 x | 22.2 x |
| EV / FCF | 66.8 x | 122 x | -544 x | -128 x | -311 x | -123 x | -47.3 x | -42 x |
| FCF Yield | 1.5% | 0.82% | -0.18% | -0.78% | -0.32% | -0.82% | -2.12% | -2.38% |
| Price to Book | 0.96 x | 2.33 x | 1.81 x | 5.03 x | 3.68 x | 4.78 x | 4.56 x | 4.19 x |
| Nbr of stocks (in thousands) | 69,926 | 69,959 | 73,732 | 73,750 | 74,971 | 74,974 | - | - |
| Reference price 2 | 30.96 | 79.10 | 143.2 | 79.85 | 65.00 | 87.45 | 87.45 | 87.45 |
| Announcement Date | 3/13/20 | 3/12/21 | 3/18/22 | 3/7/23 | 3/7/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 313.7 | 402 | 503.2 | 531.7 | 577.3 | 620 | 805.5 | 1,003 |
| EBITDA 1 | 87.2 | 122.6 | 157.4 | 160.5 | 166.7 | 180.3 | 240.9 | 309.5 |
| EBIT 1 | 62.36 | 96.7 | 128.9 | 127.2 | 129.4 | 131.5 | 176.6 | 235 |
| Operating Margin | 19.88% | 24.05% | 25.62% | 23.93% | 22.41% | 21.21% | 21.93% | 23.44% |
| Earnings before Tax (EBT) 1 | 60.37 | 90.96 | 131.4 | 112.1 | 124.2 | 134.1 | 183.8 | 216.4 |
| Net income 1 | 54.16 | 78.1 | 114.7 | 100.7 | 111.9 | 117 | 159.1 | 186.4 |
| Net margin | 17.27% | 19.43% | 22.79% | 18.93% | 19.38% | 18.87% | 19.75% | 18.59% |
| EPS 2 | 3.910 | 5.580 | 8.090 | 1.370 | 1.500 | 1.534 | 2.102 | 2.528 |
| Free Cash Flow 1 | 33.68 | 45.94 | -19.27 | -45.81 | -14.7 | -52.8 | -140.2 | -163.5 |
| FCF margin | 10.74% | 11.43% | -3.83% | -8.62% | -2.55% | -8.52% | -17.41% | -16.31% |
| FCF Conversion (EBITDA) | 38.62% | 37.47% | - | - | - | - | - | - |
| FCF Conversion (Net income) | 62.18% | 58.83% | - | - | - | - | - | - |
| Dividend per Share 2 | 3.000 | 3.250 | 3.500 | 0.7500 | 0.8000 | 0.8633 | 0.9386 | 1.102 |
| Announcement Date | 3/13/20 | 3/12/21 | 3/18/22 | 3/7/23 | 3/7/24 | - | - | - |
1CHF in Million2CHF
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2019 S2 | 2020 S1 | 2020 S2 | 2021 S1 | 2021 S2 | 2022 S1 | 2022 S2 | 2023 S1 | 2023 S2 | 2024 S1 | 2024 S2 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | 179.2 | 177.1 | 224.9 | 239.1 | 264.1 | 234.9 | 296.9 | 239.9 | 337.5 | 264 | 356 |
| EBITDA 1 | 50.7 | 53 | 69.6 | 75.5 | 81.9 | 67.3 | 93.2 | 52.5 | 114.2 | 73 | 105 |
| EBIT 1 | 37.94 | 40.26 | 56.44 | 61.95 | 66.95 | 51.56 | 75.66 | 34.82 | 94.56 | 52 | 82 |
| Operating Margin | 21.17% | 22.73% | 25.1% | 25.9% | 25.35% | 21.95% | 25.49% | 14.51% | 28.02% | 19.7% | 23.03% |
| Earnings before Tax (EBT) 1 | - | - | - | - | - | 40.36 | 71.72 | 36.92 | - | 56 | 84 |
| Net income 1 | - | 32.83 | 45.27 | 53.12 | 61.58 | 36.61 | 64.07 | 34.45 | 77.41 | 50 | 75 |
| Net margin | - | 18.53% | 20.13% | 22.21% | 23.32% | 15.59% | 21.58% | 14.36% | 22.94% | 18.94% | 21.07% |
| EPS 2 | - | 2.350 | 3.230 | 3.800 | 4.290 | 0.5000 | 0.8700 | 0.4600 | 1.040 | 0.6700 | 0.9900 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 3/13/20 | 8/21/20 | 3/12/21 | 8/27/21 | 3/18/22 | 8/25/22 | 3/7/23 | 7/27/23 | 3/7/24 | - | - |
1CHF in Million2CHF
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt 1 | 85.7 | 84.1 | - | - | - | - | 72.9 | 304 |
| Net Cash position 1 | - | - | 68.3 | 30.8 | 299 | 79.2 | - | - |
| Leverage (Debt/EBITDA) | 0.9825 x | 0.6856 x | - | - | - | - | 0.3025 x | 0.9833 x |
| Free Cash Flow 1 | 33.7 | 45.9 | -19.3 | -45.8 | -14.7 | -52.8 | -140 | -164 |
| ROE (net income / shareholders' equity) | 13% | 16.9% | 14.4% | 8.8% | 9% | 8.68% | 10.8% | 12.9% |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share 2 | 32.40 | 34.00 | 79.10 | 15.90 | 17.70 | 18.30 | 19.20 | 20.90 |
| Cash Flow per Share 2 | 4.640 | 8.220 | 6.890 | 1.260 | 3.350 | 1.860 | 2.230 | 3.040 |
| Capex 1 | 28.8 | 65.5 | 115 | 138 | 265 | 311 | 266 | 295 |
| Capex / Sales | 9.18% | 16.3% | 22.77% | 26.04% | 45.83% | 50.13% | 32.97% | 29.38% |
| Announcement Date | 3/13/20 | 3/12/21 | 3/18/22 | 3/7/23 | 3/7/24 | - | - | - |
1CHF in Million2CHF
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Year-on-year evolution of the Yield
Change in Enterprise Value/EBITDA
Trading Rating
Investor Rating
ESG Refinitiv
Sell
Buy
Mean consensus
HOLD
Number of Analysts
7
Last Close Price
87.45
CHF
Average target price
75.67
CHF
Spread / Average Target
-13.47%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +22.10% | 46.55B | |
| +46.45% | 41.84B | |
| -3.12% | 40.84B | |
| +36.10% | 32.95B | |
| -6.30% | 28.27B | |
| +18.71% | 27.78B | |
| +46.15% | 14.26B | |
| +44.52% | 13.69B | |
| +0.19% | 12.18B |
- Stock Market
- Equities
- BANB Stock
- BCHMY Stock
- Financials Bachem Holding AG
